AIM Therapeutic Agent for Kidney Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for kidney diseases, including chronic and acute renal failure, are inadequate in effectively delaying disease progression or providing reliable therapeutic options, and there is a lack of satisfactory methods for treating kidney diseases in cats, where chronic renal failure is a leading cause of death.
Innovation Solution
Development of a prophylactic or therapeutic agent using Apoptosis Inhibitor of Macrophage (AIM) or its partial peptide, or nucleic acid encoding AIM, which can be administered to improve kidney function and treat kidney diseases by stabilizing AIM expression or inducing its expression, along with a screening method using AIM knockout mice models to evaluate the effectiveness of potential treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional drug therapy is used for kidney disease, then symptoms associated with reduced kidney function are improved, but the progression of the disease cannot be sufficiently stopped
Solution Approach 1:
The patent uses AIM (apoptosis inhibitor of macrophage) as a mediator substance to intervene in the kidney disease progression pathway. AIM acts as a protective factor that prevents macrophage apoptosis and reduces renal parenchymal fibrosis, thereby addressing the limitation of conventional therapies that cannot sufficiently stop disease progression while maintaining symptom management
2Productivity
If no specific treatment is available for acute renal failure, then rapid development of treatment method is demanded, but current treatments are inadequate for providing reliable therapeutic options
Solution Approach 1:
The patent identifies and utilizes AIM, a protective factor that is naturally produced during kidney injury response. By administering AIM or substances that induce AIM expression before or during acute renal failure, the treatment aims to prevent the development of chronic renal failure and reduce mortality, providing a reliable therapeutic option that addresses both urgent treatment needs and long-term outcomes
3Ease of operation
If conventional treatments are used for feline kidney diseases, then basic symptom management is provided, but satisfactory treatment methods do not exist and chronic renal failure remains a leading cause of death
Solution Approach 1:
The patent applies the protective factor AIM specifically to feline kidney disease treatment, where it has been shown to improve renal function and reduce mortality. This represents a parameter change in treatment approach from conventional symptom management to targeted biological intervention that addresses the underlying pathology of chronic renal failure in cats
Data Source
AI summary
The present invention provides a prophylactic or therapeutic agent for a kidney disease, comprising Apoptosis Inhibitor of Macrophage (AIM) or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same, or a screening method for a prophylactic or therapeutic agent for a kidney disease, comprising using an animal obtained by subjecting a non-human mammal deficient in AIM expression to unilateral ureteral obstruction or transient kidney ischemia/reperfusion and the like.